Metalloproteinases (3.4.24) (e.g., Collagenase, Snake Venom Zinc Proteinase, Etc.) Patents (Class 424/94.67)
  • Patent number: 10969609
    Abstract: The disclosure relates to the use of contact lenses for treating ophthalmologic conditions, such as presbyopia, induced myopia, computer vision syndrome, insufficient accommodation, or a condition associated with insufficient accommodation. The contact lens may be selected based on a measured sagittal depth and/or eccentricity of the cornea. When fitted, fluid may accumulate between the cornea of the eye and the contact lens The lens may exhibit a sufficient amount of apical clearance such that when the wearer blinks, the lens moves no more than 1 mm on the eye. The lens and the eye may be structured such that bubbles greater than 0.5 mm in diameter are prevented from forming between the contact lens and the eye. The contact lens may be used in combination with a suitable bioactive agent providing for enhanced visual correction.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Osio Corporation
    Inventors: Stuart C. Grant, Alberto Osio Hernandez-Pons, John Michael Rinehart
  • Patent number: 10960060
    Abstract: A method for treating arrhythmia in a patient in need thereof comprises administering botulinum toxin to the patient. Botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: March 30, 2021
    Assignee: PENLAND FOUNDATION
    Inventor: Roland M. Williams
  • Patent number: 10853620
    Abstract: A dermal image information processing device including a memory; and a hardware component that reads data from the memory and is configured to: acquire dermal image information showing ridge lines in a papillary layer; detect an singular region in a pattern of the ridge lines; detect a position that is furthest away from the singular region; determine a region for collation based on the detected position; and perform collation of the pattern of the ridge lines using only feature points that are included in the region for collation.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: December 1, 2020
    Assignee: NEC CORPORATION
    Inventor: Masanori Mizoguchi
  • Patent number: 10828348
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 10, 2020
    Assignee: Maryland Mental Health Institute, LLC
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Patent number: 10729751
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 4, 2020
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Patent number: 10653738
    Abstract: Topical medications to treat the physical effects of bruises and burns. For bruises, the topical medication preferably includes therapeutically effective amounts of vasoconstrictor, such as phenylephrine HCL USP, an anti-inflammatory, such as Arica, and compounding agents. In one embodiment, the compounding agents are a Versabase® gel which includes water, ammonium acryloyldimethyltaurate copolymer, aloe barbadensis leaf juice powder, allatoin, disodium EDTA, methylchloroisothiazolinone and methylisothiazolinone. For burns, the topical medication preferably combines therapeutically effective amounts of an active anti-bacterial compound, such as silver sulfadiazine, an anesthetic, such as lidocaine, and a histamine blocker, such as diphenhydramine, with suitable compounding agents, such as Versabase® gel. Both the anti-bruise and anti-burn medications of the present invention can advantageously be formulated in solutions, lotions, creams, ointments, gels, foams or transdermal patches.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: May 19, 2020
    Assignee: Meridian Research and Development Inc.
    Inventor: Ronald F. DeMeo
  • Patent number: 10603365
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: March 31, 2020
    Assignee: ENDO GLOBAL VENTURES
    Inventor: Wayne K. Herber
  • Patent number: 10548925
    Abstract: A composition for use in treating penile defects, including erectile dysfunction and Peyronie's disease, is provided. The composition includes adipose tissue and stem cells. The stem cells may be derived from adipose tissue. In embodiments the composition includes additional additives such as growth factors, anti-inflammatories, antioxidants, compositions useful for wound healing, and collagenases. Also provided is a method of treating a penile defect in a patient. The method includes providing a composition containing adipose tissue and stem cells, and implanting that composition into a patient in need of treatment for a penile defect. In some embodiments the patient has Peyronie's disease. In other embodiments, the patient has erectile dysfunction.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: February 4, 2020
    Inventor: Michael P. Zahalsky
  • Patent number: 10369190
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 6, 2019
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Patent number: 10131703
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: November 20, 2018
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10119131
    Abstract: The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum. The method utilizes an improved medium for the cultivation of Clostridium histolyticum which includes a non-meat-derived (i.e., non-mammalian) peptone or vegetable peptone. The method includes one or more of: (1) reducing glucose content in the meat-free or vegetable-derived media; and (2) increasing the salt concentration in the meat-free or vegetable-derived media. Also provided is a drug product which includes collagenase I and collagenase II at an optimized fixed mass ratio, and which has a purity of greater than at least 95%.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: November 6, 2018
    Assignee: BIOSPECIFICS TECHNOLOGIES CORP.
    Inventors: Thomas L. Wegman, Bo Yu
  • Patent number: 10117892
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 6, 2018
    Assignee: Allergan, Inc.
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zachary Dominguez, Edwin Kayda
  • Patent number: 10111938
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 30, 2018
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Patent number: 10039770
    Abstract: A method of treating atrophic cutaneous scarring in humans is claimed. The method involves the topical application of a therapeutic amount of prostaglandin F2-alpha (PGF 2?) or a PGF 2? analog directly to the area of atrophic scarring.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 7, 2018
    Assignee: Galderma S.A.
    Inventor: Warren J. Scherer
  • Patent number: 10022270
    Abstract: Methods and systems for performing laser-assisted surgery on an eye form a layer of bubbles in the Berger's space of the eye to increase separation between the posterior portion of the lens capsule of the eye and the anterior hyaloid surface of the eye. A laser is used to form the layer of bubbles in the Berger's space. The increased separation between the posterior portion of the lens capsule and the anterior hyaloid surface can be used to facilitate subsequent incision of the posterior portion of the lens capsule with decreased risk of compromising the anterior hyaloid surface. For example, the layer of bubbles can be formed prior to performing a capsulotomy on the posterior portion of the lens capsule.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: July 17, 2018
    Assignee: OPTIMEDICA CORPORATION
    Inventors: Georg Schuele, Julian Stevens, Dan E. Andersen
  • Patent number: 9808515
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: November 7, 2017
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Patent number: 9737570
    Abstract: The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. The composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: August 22, 2017
    Assignees: National Taiwan University, Academia Sinica
    Inventors: Sung-Jan Lin, Mai-Yi Fan, Yu-Ju Chen, Chia-Feng Tsai
  • Patent number: 9603910
    Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 28, 2017
    Assignee: FIDIA FARMACEUTICI S.p.A.
    Inventors: Susanna Vaccaro, Giovanni Gennari, Lanfranco Callegaro, Antonio Giannelli, Salvatore Caruso
  • Patent number: 9408864
    Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: August 9, 2016
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Akihiro Yoneda, Hirotoshi Ishiwatari
  • Patent number: 9254314
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 9, 2016
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Publication number: 20150147313
    Abstract: The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 28, 2015
    Inventors: Marcos Castanheira Alegria, Lucidio Cristoväo Fardelone, Marina Baiochi Riboldi Delalana, Josef Ernst Thiemann, Spartaco Astolfi Filho, Roberto Carlos Debom Moreira, Ogari de Castro Pacheco
  • Publication number: 20150132281
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 14, 2015
    Inventors: Irit Sagi, Eitan Wong, Ran Afik
  • Publication number: 20150132283
    Abstract: The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 14, 2015
    Inventor: Gary E. Borodic
  • Publication number: 20150132282
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 14, 2015
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Publication number: 20150104439
    Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Josee Roy, Susan J. Drapeau, Jeffrey C. Marx
  • Publication number: 20150093373
    Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 2, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Edward C. DEMPSEY
  • Publication number: 20150093372
    Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Applicant: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee
  • Publication number: 20150086531
    Abstract: Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 26, 2015
    Applicant: Allergan, Inc.
    Inventors: Guang-Liang Jiang, Catherine Turkel
  • Publication number: 20150086533
    Abstract: A method of treating anxiety disorder comprising the steps of: identifying a subject with one or more symptoms of an anxiety disorder; a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of anxiety disorder.
    Type: Application
    Filed: November 28, 2014
    Publication date: March 26, 2015
    Inventor: Gary E. Borodic
  • Publication number: 20150086532
    Abstract: A method of treating major depression comprising the steps of: identifying a subject with one or more symptoms of a depressive disorder; and administering a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of depression.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 26, 2015
    Inventor: Gary E. Borodic
  • Publication number: 20150079069
    Abstract: Methods for modification of mechanical properties or a shape of a mammalian tissue, excluding scar, blood clot, fat; including a step of contacting the tissue with an isolated eukaryotic endopeptidase in an amount sufficient to cause a modification of mechanical properties of the tissue or its shape, but insufficient to cause degradation of the tissue's into incohesive parts, and to the use of eukaryotic endopeptidases for use in methods for treatment of the mammalian body.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Applicant: ELASTOMICS AB
    Inventor: Aleksei Rozkov
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Publication number: 20150064166
    Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.
    Type: Application
    Filed: November 5, 2014
    Publication date: March 5, 2015
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
  • Publication number: 20150064167
    Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Inventors: Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
  • Publication number: 20150060462
    Abstract: A portable neurotoxin injection tray apparatus that includes a vial section with multiple compartments. Each compartment is capable of storing at least one neurotoxin vial or at least one saline vial. The apparatus also includes a dosage compartment with a tilted support member for positioning at least one of the neurotoxin vials in a tilted orientation. Further, the apparatus includes an injection syringe section that includes multiple compartments, where each compartment is designated to store at least one injection syringe filled with a different dosage of neurotoxin.
    Type: Application
    Filed: September 4, 2014
    Publication date: March 5, 2015
    Inventors: Rand Colbert, Russell G. Olsen
  • Publication number: 20150064165
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zackary Dominguez, Edwin Kayda
  • Publication number: 20150064163
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.
    Type: Application
    Filed: September 2, 2012
    Publication date: March 5, 2015
    Applicant: LIFENET HEALTH
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Publication number: 20150056179
    Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.
    Type: Application
    Filed: April 17, 2013
    Publication date: February 26, 2015
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari
  • Publication number: 20150044171
    Abstract: Compositions and methods for the treatment of thrombotic thrombocytopenic purpura are disclosed.
    Type: Application
    Filed: June 23, 2014
    Publication date: February 12, 2015
    Inventor: X. Long Zheng
  • Publication number: 20150037402
    Abstract: Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within into the gastrointestinal (GI) tract in need of treatment. Preferably, the formulation is applied via a roller, sponge or nozzle that is attached to an endoscope.
    Type: Application
    Filed: February 4, 2013
    Publication date: February 5, 2015
    Inventors: Michael B. Chancellor, Jonathan H. Kaufman
  • Publication number: 20150030583
    Abstract: The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 29, 2015
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Malcolm A.S. Moore, Server A. Ertem
  • Publication number: 20150030584
    Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 29, 2015
    Applicant: SYNTAXIN LIMITED
    Inventor: Andreas Rummel
  • Publication number: 20150010533
    Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Inventor: Eric R. First
  • Publication number: 20150010532
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 8, 2015
    Inventor: Wayne K. Herber
  • Publication number: 20150004153
    Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: HOMS, LLC
    Inventor: Allen Jones
  • Patent number: 8920795
    Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 30, 2014
    Assignee: Medy-Tox Inc.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
  • Publication number: 20140377249
    Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Susanna VACCARO, Giovanni GENNARI, Lanfranco CALLEGARO, Antonio GIANNELLI, Salvatore CARUSO
  • Publication number: 20140377319
    Abstract: Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid.
    Type: Application
    Filed: April 18, 2012
    Publication date: December 25, 2014
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Eric C. Leuthardt, Daniel W. Moran, David Holtzman, Philip Bayly, David Brody, Ralph G. Dacey, Sam Fok, David Jeremiah Garrison, Guy M. Genin, Eriks Lusis, Rohit Pappu, Jingwei Xie, Greg Zipfel
  • Publication number: 20140377248
    Abstract: This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Inventors: Swen Grein, Kerstin Hoelscher, Annett Eylenstein
  • Patent number: 8916150
    Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: December 23, 2014
    Assignee: CNSS IP Holdings, Inc.
    Inventor: Charles N. S. Soparkar